HowardLSofenMD

Dermatology • Los Angeles, CA

Medical Director of Dermatology Research Associates; Associate Clinical Professor of Medicine/Dermatology Geffen School of Medicine, UCLA

Join to view full profile

Dr. Sofen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sofen's full profile

Already have an account?

Office
8930 S Sepulveda Blvd
Ste 114
Los Angeles, CA 90045
Phone+1 310-337-7171

Fax+1 310-337-1081

Summary

Dr. Howard Sofen is a dermatologist in Los Angeles, CA and is affiliated with Ronald Reagan UCLA Medical Center. He received his medical degree from Drexel University College of Medicine and has been in practice 36 years. He is experienced in general dermatology, melanoma and cutaneous malignancies, and psoriasis; eczema.

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Dermatology, 1982 - 1985
University of Southern California/Los Angeles General Medical Center (USC/LA General)Internship, Internal Medicine, 1981 - 1982
Drexel University College of MedicineClass of 1981

Certifications & Licensure

CA State Medical License 1982 - 2025
American Board of Dermatology Dermatology

Awards, Honors, & Recognition

Fellow (FAAD) American Academy of Dermatology

Clinical Trials

The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis Start of enrollment: 2009 Nov 01
Completed
Phase 3
Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris Start of enrollment: 2014 Mar 19
Completed
Phase 2
A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis Start of enrollment: 2015 Aug 01
Completed
Phase 3
Study of Glycopyrronium in Subjects With Axillary Hyperhidrosis Start of enrollment: 2015 Aug 01
Completed
Phase 3
Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis Start of enrollment: 2015 Aug 01
Completed
Phase 3
A Study To Evaluate ASN002 In Subjects With Atopic Dermatitis Start of enrollment: 2017 Apr 12
Completed
Phase 1
This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is Start of enrollment: 2018 Sep 17
Completed
Phase 2
A Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it is Start of enrollment: 2019 Mar 18
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: A randomised controlled trial secondary analysis at 3 years.
John E Harris, Amit G Pandya, Mark Lebwohl, Iltefat H Hamzavi, Pearl Grimes
Skin Health and Disease. 2024-12-01
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials.
Neil J Korman, Richard B Warren, Jerry Bagel, April W Armstrong, Melinda Gooderham
The Journal of Dermatological Treatment. 2024-12-01
Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis For Up to 3 Years: An Open-Label Extension of Randomized Clinical Trials.
April W Armstrong, Mark Lebwohl, Richard B Warren, Howard Sofen, Shinichi Imafuku
JAMA Dermatology. 2024-11-27

Press Mentions

Top 5 Small Cosmetic Dermatology SitesMay 4th, 2023
Asana BioSciences to Present Additional Efficacy Data from Chronic Hand Eczema Phase 2b Trial of Oral SYK/JAK Inhibitor Gusacitinib at AAD VMX Late-Breaking SessionApril 22nd, 2021
Improvements in Chronic Hand Eczema Seen with Oral Gusacitinib in Phase 2 StudyNovember 19th, 2020
Join now to see all

Professional Memberships

American Academy of Dermatology - AAD
Fellow